H-016

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameH-016
Drug Alias NameH-016
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungThyroid NeoplasmsThyroid Cancer, Papillary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Carephar Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Carephar Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungThyroid NeoplasmsThyroid Cancer, Papillary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A